What is industry capacity utilization for biomanufacturing among the major systems/platforms (mammalian, microbial, and advanced therapies)? Is there too much capacity or is the market tight? The latest episode of DCAT Value Chain Insights’ Production to Prescription podcast answers that and these all-important questions: 

Is biomanufacturing outsourcing up or down? Are biopharma companies outsourcing more or less? And what is the impact on evolving trade policy on biomanufacturing supply chains. 

This episode features Eric Langer, MBA, Managing Partner & President, and Renaud Jacquemart, PhD, MBA, Senior Advisor, both of BioPlan Associates, a strategic consulting and business intelligence firm for the biopharmaceutical and life-sciences industries. They provided an in-depth look at biopharmaceutical manufacturing capacity and production trends. BioPlan Associates recently released its annual study on this topic.  

DCAT Value Chain Insights’ Production to Prescription podcast features thought leaders with expert views on the major happenings impacting the global bio/pharmaceutical manufacturing value chain and industry performance.  

Click here for the latest episode and here for the full 2025 schedule.